



---




## Supplementary Materials



**Supplementary Figure S1. Expression of tyrosine kinase receptor genes on HeLa and TOS1 cells.** Total RNA extracted from HeLa and TOS1 cells ( $5 \times 10^4$ ) was analyzed by RT-qPCR using specific primers for *VEGFR2*, *PDGFRB*, *KIT*, *FLT3*, and *GAPDH*. PCR products were analyzed on 2% agarose gels.



**Supplementary Figure S2. Cytotoxic effects of pazopanib, axitinib, and everolimus in TOS1 cells.** TOS1 cells were treated with pazopanib (0, 3.125, 6.25, 12.5, and 25  $\mu\text{M}$ ), axitinib (0, 3.125, 6.25, 12.5 and 25  $\mu\text{M}$ ), or everolimus (0, 5, 10, 20, 40 and 80  $\mu\text{M}$ ) at 37 °C for 24 or 48 h. Cell viability was measured using the CCK-8 assay. Values represent means  $\pm$  standard errors (SEs) of three independent experiments.



**Supplementary Figure S3. Cytotoxic effects of pazopanib, axitinib, and everolimus in SAL-pretreated TOS1 cells.** TOS1 cells were pretreated with SAL (50 μg/mL) at 37 °C for 24 h. The SAL-pretreated cells TOS-1 cells were treated with pazopanib (0 and 25 μM), axitinib (0 and 25 μM), or everolimus (0, 35, and 40 μM) at 37 °C for 24 or 48 h. Cell viability was measured by the CCK-8 assay. Values represent means ± SEs of three independent experiments. \* $p < 0.05$  versus non-treated control cells.